DDrare: Database of Drug Development for Rare Diseases

Searched query = "Cerebrotendinous xanthomatosis", "27-hydroxylase deficiency", "CYP27 deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Blinded CDCA 250 mg TID; Blood tests; CDCA; CDCA Weight-Based Dose TID; Chenodeoxycholic Acid; Chenodeoxycholic acid; FPF1011; Lovastatin; Open-Label CDCA 250 mg TID; Rescue Medication CDCA 250 mg TID

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01613898 (ClinicalTrials.gov)	August 2010	22/5/2012	Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis	Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis	Cerebrotendinous Xanthomatosis (CTX)	Biological: Blood tests	Sheba Medical Center	NULL	Recruiting	10 Years	N/A	Both	17	N/A	Israel

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01613898
(ClinicalTrials.gov)

August 2010

22/5/2012

Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis

Cerebrotendinous Xanthomatosis (CTX)

Biological: Blood tests

Sheba Medical Center

NULL

Recruiting

10 Years

N/A

Both

N/A

Israel